CDXS
Codexis Inc.

2,233
Loading...
Loading...
News
all
press releases
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of +5.88% and +2.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
More News
News Placeholder
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -6.52% and -52.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -14.46% and -66.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates
Vertex (VRTX) delivered earnings and revenue surprises of +6.60% and +2.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates
Regeneron (REGN) delivered earnings and revenue surprises of +60.52% and +9.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates
Zacks·5mo ago
News Placeholder
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
Zacks·5mo ago
News Placeholder
Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates
Zacks·5mo ago
News Placeholder
Crosswalk Therapeutics Announces Acquisition of Rare Disease Assets from Codexis, Inc.
Crosswalk Therapeutics Announces Acquisition of Rare Disease Assets from Codexis, Inc. Crosswalk Therapeutics Announces Acquisition of Rare Disease Assets from Codexis, Inc. PR Newswire CAMBRIDGE...
PR Newswire·1y ago
News Placeholder
Codexis, Inc. (NASDAQ:CDXS) Sees Significant Decrease in Short Interest
Codexis, Inc. (NASDAQ:CDXS - Get Free Report) was the target of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 2,290,000 shares, a decrease of...
Ticker Report·1y ago

Latest CDXS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.